VIDEO: Elamipretide for dry AMD progresses to phase 3 studies

ByDavid S. Boyer, MD

ByAnthony DeFino

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, discusses targeting mitochondria in retinal disease treatment.

According to Boyer, mitochondria are a “very good area to attack” when treating patients with geographic atrophy in dry age-related macular degeneration, with the ReCLAIM-2 study showing a reduction in ellipsoid zone attenuation progression and improvement in low-luminance vision after treatment with subcutaneous elamipretide. Elamipretide is now progressing to phase 3 studies.

Published by:

Sources/Disclosures

Collapse

Source:

Boyer D. The role of mitochondria in the treatment of dry macular degeneration. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Boyer reports being an advisor and investigator for Stealth BioTherapeutics.

Clinical Trials at the Summit meeting

Read more

VIDEO: Elamipretide for dry AMD progresses to phase 3 studies

Related Content